Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Precision Therapeutics Inc.
Data Published in Anticancer Research Show ChemoFx Assay Results Correlate With Outcomes in Breast Cancer
July 17th, 2008
Precision Therapeutics Inc. announced that results from the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlate with pathologic complete response in breast cancer patients treated with neoadjuvant (pre-operative) chemotherapy. Data published in Anticancer Research show that the assay accurately predicted response to therapy 75% of the time. This study, done in conjunction with US Oncology, a leading cancer research and treatment network, represents the company's first publication in the breast cancer setting. "Achieving pathologic complete response is an important goal for patients in the...
Source: Women's Health Weekly (2008-07-17)
|
